The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Lineage Cell Therapeutics Inc (AMEX: LCTX) closed at $0.60 in the last session, down -4.12% from day before closing price of $0.63. In other words, the price has decreased by -$4.12 from its previous closing price. On the day, 1.77 million shares were traded. LCTX stock price reached its highest trading level at $0.6766 during the session, while it also had its lowest trading level at $0.5761.
Ratios:
We take a closer look at LCTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.48 and its Current Ratio is at 2.48. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 27 ’25 when BROADWOOD PARTNERS, L.P. bought 7,894,737 shares for $0.76 per share. The transaction valued at 6,000,000 led to the insider holds 49,560,992 shares of the business.
Howe Jill Ann bought 15,000 shares of LCTX for $8,850 on Nov 26 ’24. The Chief Financial Officer now owns 25,500 shares after completing the transaction at $0.59 per share. On Nov 26 ’24, another insider, Samuel George A. III, who serves as the General Counsel of the company, bought 15,000 shares for $0.60 each. As a result, the insider paid 9,000 and bolstered with 22,184 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 137146432 and an Enterprise Value of 130151080. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.18 while its Price-to-Book (P/B) ratio in mrq is 1.71. Its current Enterprise Value per Revenue stands at 21.04 whereas that against EBITDA is -6.083.
Stock Price History:
The Beta on a monthly basis for LCTX is 1.22, which has changed by -0.42307693 over the last 52 weeks, in comparison to a change of 0.22208416 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $1.61, while it has fallen to a 52-week low of $0.48. The 50-Day Moving Average of the stock is 3.60%, while the 200-Day Moving Average is calculated to be -30.35%.
Shares Statistics:
According to the various share statistics, LCTX traded on average about 2.54M shares per day over the past 3-months and 1970360 shares per day over the past 10 days. A total of 220.42M shares are outstanding, with a floating share count of 219.47M. Insiders hold about 0.43% of the company’s shares, while institutions hold 47.63% stake in the company. Shares short for LCTX as of 1730332800 were 15938784 with a Short Ratio of 10.65, compared to 1727654400 on 15221739. Therefore, it implies a Short% of Shares Outstanding of 15938784 and a Short% of Float of 10.89.
